Article
The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.
Future oncology (London, England) - 1 Jun 2020
Liang Jin, Chen Dedian, Chen Liyao, She Xueke, Zhang Hushan, Xiao Yanbin
Abstract excerpt
Sarcomas are rare and heterogeneous malignant tumors of mesenchymal origin. A total of 25-50% of patients treated with initial curative intent will develop as recurrent and metastatic disease. In the recurrent and metastatic setting, effect of chemotherapy is limited; therefore, more effective therapies are urgently desired. As a brake for activation of T cell, PD-1/PD-L1 plays a crucial role in the progression...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.